A conjugate of lysozyme and aminoglycosides used in non-human animals to combat diseases caused by Gram-positive and Gram-negative bacteria.
By combining lysin with aminoglycoside antibiotics, the problems of pathogen resistance and insufficient combination therapy in the treatment of mastitis have been solved, achieving synergistic therapeutic effects against Gram-positive and Gram-negative pathogens and reducing the economic losses from bovine mastitis.
Patent Information
- Application Number
- CN202611218302.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-02-17
- Filing Date
- 2018-02-14
- Publication Date
- 2026-11-17
AI Technical Summary
In existing technologies, when treating mastitis with antibiotics, pathogens are prone to developing drug resistance, and there is a lack of effective combination therapy regimens to synergistically treat bovine mastitis caused by Gram-positive and Gram-negative pathogens.
By combining lysozyme with aminoglycoside antibiotics, different mechanisms of action can be used synergistically to target Gram-positive and Gram-negative pathogens, providing systemic or local administration routes, including oral, parenteral, and transdermal routes.
It significantly expands antibacterial properties, reduces the development of drug resistance in pathogens, and is particularly effective in treating Gram-positive and Gram-negative pathogens in bovine mastitis, thus reducing economic losses.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
[0001] This application is a divisional application of PCT / EP2018 / 053667, filed on February 14, 2018, entitled "A conjugate of lysozyme and aminoglycosides for combating diseases caused by Gram-positive and Gram-negative bacteria in non-human animals". The original application entered the Chinese national phase on July 30, 2019, with the national phase application number 201880009227.9. Technical Field
[0002] This invention relates to a combination of lysozyme and aminoglycoside antibiotics for treating diseases in non-human animals caused by Gram-positive and Gram-negative bacteria. The invention has proven particularly suitable for treating mastitis in non-human animals. In particular, bovine mastitis can be effectively treated using this invention. Background Technology
[0003] Mastitis is an inflammation of the mammary tissue and remains the most common and costly disease in dairy cows. Economic losses from mastitis occur in both the subclinical and clinical stages of the disease. Losses from subclinical mastitis are well documented. A doubling of somatic cell counts (SCC) exceeding 50,000 cells / ml results in a daily loss of 0.4 kg of milk for first-time lactating cows and 0.6 kg for older cows (Hortet P, H. Seegers. 1998. Calculated milk production losses associated with elevated somatic cell counts in dairycows: review and critical discussion. Vet Res. 29(6):497-510). Losses from clinical mastitis include discarded milk, a temporary decrease in milk production, and premature culling. Mastitis should be treated against the causative bacteria whenever possible.
[0004] In the Irish Veterinary Journal, Volume 62, Supplement 40-44, 2009, Pyörälä S offered the following recommendations for antibacterial treatment of clinical mastitis caused by different pathogens:
[0005]
[0006] A recently developed pharmaceutical composition for treating mastitis in dairy cows is Ubrolexin®, a broad-spectrum antibiotic targeting bacteria that cause both Gram-positive and Gram-negative mastitis. Ubrolexin® is a combination of cephalexin and kanamycin, indicated for the treatment of clinical mastitis caused by Staphylococcus aureus, Streptococcus bacillus, Streptococcus lactis, and Escherichia coli. Cephalexin (a cephalosporin antibiotic) works by irreversibly binding to D-alanine transpeptidase, which disrupts bacterial cell wall synthesis. Kanamycin (an aminoglycoside antibiotic) works by attaching to the 30S subunit of the membrane-associated ribosome and inhibiting or interfering with bacterial protein synthesis.
[0007] Therefore, antibiotics, especially aminoglycosides combined with other antibiotic substances, are known in themselves.
[0008] A recurring problem with existing antibiotics is that pathogens can develop resistance to the drugs used to treat the diseases they cause. Therefore, there is a constant search for new active pharmaceutical ingredients. The problem of resistance development is even more pronounced when antibiotic substances that do not act synergistically but target only different pathogens are used in combination. In those cases, pathogens that are not the primary target of the first antibiotic can gradually develop complete resistance to that first antibiotic.
[0009] Lysozyme was first isolated from the fermentation broth of *Lysobacter* sp. SC-14076 (ATCC 53042). Independently, scientists discovered katanosin A and B in soil bacteria associated with *Cytophaga* (producing strain PBJ-5356). Katanosin B was shown to be identical to lysozyme. Bacterial cell wall biosynthesis is the primary target of these antibiotics; however, the mechanism of action differs from that of vancomycin. Lysozyme is a cyclic depsipetide containing several non-proteinogenic D- and L-amino acids.
[0010] In US 4,754,018, the natural product lysozyme and some of its derivatives are described as having antibacterial activity. The isolation and antibacterial activity of lysozyme are also described in EP 196042 A1 and JP 01-132600.
[0011] The antibacterial activities of lysozyme and katanosin A are further described in O'Sullivan, J. et al., J. Antibiot. (1988) 41:1740-1744, Bonner, DP et al., J. Antibiot. (1988) 41:1745-1751, Shoji, J. et al., J. Antibiot. (1988) 41:713-718 and Tymiak, AA et al., J. Org. Chem. (1989) 54:1149-1157.
[0012] Unlike cephalexin and kanamycin, lysozyme has been shown to interact directly with bacterial cell wall precursor lipid II (Lee, W. et al., Am. Chem. Soc. (2016) 138(1):100-113 and Breukink E. and de Kruijff B., Nat. Rev. Drug Disc. (2006) 5:321-323). Derivatives of lysozyme are the subject of the following patent applications: WO 2004 / 099239 A1, WO 2006 / 042653 A1, WO 2006 / 042654 A1, WO2006 / 042655 A1, WO 2006 / 048139 A1, WO 2006 / 048140 A1, WO 2006 / 048156 A1, WO 2007 / 085456 A1, WO 2007 / 118691 A1 and WO 2007 / 118693 A1.
[0013] None of the listed prior art techniques address the use of lysozyme to treat bovine mastitis. In particular, no prior art combines lysozyme with other antibiotic substances for the treatment of mastitis. Especially, there are few suitable options in the art for the treatment of bovine mastitis, a major cause of loss in commercial agriculture.
[0014] Although a surprising and significant benefit of using lysozyme alone in the treatment of bovine mastitis, which is primarily caused by Gram-positive pathogens, particularly Staphylococcus, Streptococcus, Trueperella, and / or Corynebacterium, remains uncertain due to its resistance-disrupting properties, there is still uncertainty regarding the efficacy of lysozyme as a potential agent against Gram-negative pathogens and its potential synergistic effects with other antibiotic substances. Summary of the Invention
[0015] Therefore, there remains a need in the art for a treatment of mastitis (particularly bovine mastitis) that does not suffer from the disadvantage of bacterial resistance to the active ingredient and can synergistically address both Gram-positive and Gram-negative pathogens. The object of this invention is to provide a solution for this purpose. Therefore, this invention particularly relates to a combination of lysin for treating mastitis with at least one aminoglycoside antibiotic. In particular, the treatment of bovine mastitis, as this type of commercially most relevant disease, is the object of this invention. Surprisingly, it has been found that the combination of lysin and aminoglycoside antibiotics synergistically results in an expansion of antimicrobial activity against Gram-positive and Gram-negative pathogens associated with diseases caused by those pathogens in non-human animals. The effect of this synergistic effect is particularly pronounced in female animals suffering from mastitis caused by these pathogens, and bovine mastitis has proven to be the most commercially relevant application of the invention described herein.
[0016] In the context of this invention, the term "lysozyme" refers to the substance with CAS number 118374-47-3 and its physiologically acceptable salts. Lysozyme has the following structure:
[0017]
[0018] Mastitis in cows awaiting treatment, especially mastitis in dairy cows.
[0019] Physiologically acceptable salts of lysozyme include acid addition salts of inorganic acids, carboxylic acids, and sulfonic acids, such as salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid, and benzoic acid.
[0020] Physiologically acceptable salts of lysozyme also include salts of conventional bases, such as and preferably alkali metal salts (e.g., sodium and potassium salts), alkaline earth metal salts (e.g., calcium and magnesium salts), and ammonium salts derived from ammonia or organic amines having 1-16 carbon atoms, such as and preferably ethylamine, diethylamine, triethylamine, ethyl diisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine, and N-methylpiperidine.
[0021] In the context of this invention, the term "aminoglycoside antibiotic" or "aminoglycoside" refers to oligosaccharide substances composed of cyclohexane-sugar groups and amino-sugar groups, both functionally characterized by attachment to the 30S subunit of membrane-associated ribosomes, thereby interfering with (particularly) bacterial protein biosynthesis. The non-limiting and non-exhaustive members of the aminoglycoside group according to the invention are those selected from amikacin, apramycin, neomycin B, genimycin (G418), gentamicin, kanamycin, netilmicin, neomycin, paromomycin, cefotaxime, spectinomycin, streptomycin, and tobramycin.
[0022] Like lysozyme, "aminoglycoside antibiotics" or "aminoglycosides" also include their physiologically acceptable salts. Therefore, physiologically acceptable salts of aminoglycosides include acid addition salts of inorganic acids, carboxylic acids, and sulfonic acids, as well as salts of the conventional bases listed in relation to lysozyme in the context of this invention.
[0023] Lysozyme and aminoglycosides can act systemically and / or locally. For this purpose, it can be administered in appropriate ways, such as by oral, parenteral, pulmonary, nasal, sublingual, tongue, sublingual, rectal, intra-articular, skin or transdermal routes, or as an implant or stent.
[0024] Lysozyme and aminoglycosides can be administered in forms suitable for these routes of administration.
[0025] Suitable for oral administration are those forms of administration that act according to existing technology and deliver lysozyme and aminoglycosides rapidly and / or in a modified manner, and that contain lysozyme and aminoglycosides in crystalline and / or amorphous and / or dissolved forms, such as tablets (uncoated or coated tablets, such as those with enteric coatings or coatings that are insoluble or have delayed dissolution and control the release of lysozyme), tablets that disintegrate rapidly in the oral cavity, or films / thin tablets, films / lyophilized forms, capsules (e.g., hard or soft gelatin capsules), sugar-coated tablets, granules, pills, powders, emulsions, suspensions, aerosols, or solutions.
[0026] Parenteral administration can avoid absorption steps (e.g., intramammary, intravenous, intraarterial, intracardiac, intraspinal, or intralumbar spinal cord) or involve absorption (e.g., intramuscular, subcutaneous, intradermal, percutaneous, or intraperitoneal). Suitable parenteral administration forms are particularly injectable and infusion formulations in the form of solutions, suspensions, emulsions, lyophilized products, or sterile powders.
[0027] Other drug forms suitable for other routes of administration include aqueous suspensions (lotions, shaken mixtures), lipophilic suspensions, ointments, creams, transdermal therapy systems (e.g., patches), emulsions, pastes, foams, powders, implants, or stents.
[0028] Lysozyme and aminoglycosides can be converted into the aforementioned dosage forms. This can be done in a manner known per se by mixing with inert, non-toxic, and pharmaceutically suitable excipients. These excipients include, in particular, carriers (e.g., microcrystalline cellulose, lactose, mannitol), solvents (e.g., liquid polyethylene glycol), emulsifiers and dispersants or wetting agents (e.g., sodium lauryl sulfate, polyoxysorbate oleate), binders (e.g., polyvinylpyrrolidone), synthetic and natural polymers (e.g., albumin), stabilizers (e.g., antioxidants, such as ascorbic acid), colorants (e.g., inorganic pigments, such as iron oxide), and taste and / or flavor masking agents. Detailed Implementation
[0029] The invention will be further described with reference to the following aspects and embodiments. Unless the context clearly indicates otherwise, these can be freely combined.
[0030] One embodiment involves a conjugate of lysozyme for treating mastitis and at least one aminoglycoside antibiotic, wherein the lysozyme and the aminoglycoside antibiotic are administered intramammarily. The aminoglycoside antibiotic is preferably neomycin or kanamycin. More preferably, the mastitis is bovine mastitis.
[0031] Another embodiment involves a conjugate of lysozyme for treating mastitis with at least one aminoglycoside antibiotic, wherein the mastitis is clinically evident mastitis. The aminoglycoside antibiotic is preferably neomycin or kanamycin. More preferably, the mastitis is bovine mastitis.
[0032] Another embodiment involves a conjugate of lysozyme for treating mastitis with at least one aminoglycoside antibiotic, wherein the mastitis is subclinical bovine mastitis. The aminoglycoside antibiotic is preferably neomycin or kanamycin. More preferably, the mastitis is bovine mastitis.
[0033] Another embodiment involves a combination of lysozyme for treating mastitis and at least one aminoglycoside antibiotic, wherein the lysozyme is provided at a dose of 25 to 1000 mg per quarter, preferably at a dose of 50 to 500 mg per quarter, more preferably at a dose of 100 to 300 mg per quarter. Most preferably, the mastitis is bovine mastitis.
[0034] In a preferred embodiment of this implementation, the lysozyme conjugate is composed of neomycin or kanamycin, preferably neomycin.
[0035] In appropriate circumstances, deviations from the prescribed amounts may be necessary; this is especially true as it varies with body weight, route of administration, individual response to the active ingredient, the nature of the formulation, and the time or interval of administration. Therefore, in some cases, using less than the minimum amount mentioned above may be sufficient, while in others, the prescribed upper limit must be exceeded. In cases of administering larger doses, it may be recommended to divide them into multiple individual doses throughout the day.
[0036] Depending on the actual aminoglycoside antibiotic used according to the invention, the above-mentioned dosage can vary, and therefore the ratio of lysozyme to it can vary.
[0037] The results are very positive for both Gram-negative and Gram-positive pathogens; therefore, a ratio of at least 0.1 for lysin to aminoglycoside antibiotics is preferred. A ratio of at least 0.2 yields even better results, while a more preferred ratio is at least 1:1, and even more preferred is at least 2:1. The most preferred ratio is at least 4:1.
[0038] Another embodiment involves a conjugate of lysozyme for treating mastitis with at least one aminoglycoside antibiotic, wherein the mastitis is caused by Gram-positive and Gram-negative bacteria. Preferably, the mastitis is bovine mastitis.
[0039] More preferably, this involves a combination of lysozyme for treating bovine mastitis with at least one aminoglycoside antibiotic, wherein the bovine mastitis is caused by Staphylococcus, Streptococcus, Trueperella, Corynebacterium, and / or Escherichia bacteria.
[0040] In particular, bovine mastitis can be caused by Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus lactis, Streptococcus brasiliensis, Streptococcus agalactiae, and / or Escherichia coli.
[0041] In addition, bovine mastitis can be caused by *Trueperella pyogenes* and / or *Escherichia coli*.
[0042] Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus lactis, Streptococcus brasiliensis, Streptococcus agalactiae, Cryptococcus pyogenes, and Corynebacterium bovis are the most common pathogens in cases of bovine mastitis, while reinfection with Escherichia coli is common, and they have all been found to be particularly sensitive to treatment with a combination of lysin according to the invention and at least one aminoglycoside antibiotic. Mastitis can also become clinically relevant simply by the presence of Escherichia coli bacteria.
[0043] Another aspect of the invention is the formulation of a pharmaceutical composition for intramammary administration, wherein the composition comprises lysin and at least one aminoglycoside antibiotic. Preferably, the composition is formulated for application into the bovine udder. More preferably, the composition further comprises a pharmaceutically acceptable excipient, particularly a pharmaceutically acceptable carrier.
[0044] These excipients include, in particular, carriers (e.g., microcrystalline cellulose, lactose, mannitol), solvents (e.g., liquid polyethylene glycol), emulsifiers and dispersants or wetting agents (e.g., sodium dodecyl sulfate, polyoxyethylene sorbitan oleate), binders (e.g., polyvinylpyrrolidone), synthetic and natural polymers (e.g., albumin), stabilizers (e.g., antioxidants, such as ascorbic acid), colorants (e.g., inorganic pigments, such as iron oxide), and flavor and / or aroma masking agents.
[0045] Another aspect of the invention is the use of lysozyme and at least one aminoglycoside antibiotic in the preparation of a medicament for treating mastitis. Use in the preparation of a medicament for treating bovine mastitis is preferred.
[0046] In one embodiment of the invention, bovine mastitis is clinically recognized bovine mastitis.
[0047] In another embodiment of the invention, the bovine mastitis is subclinical bovine mastitis.
[0048] In another embodiment of the invention, bovine mastitis is caused by Staphylococcus spp., Streptococcus spp., Cryptococcus pyogenes, Corynebacterium spp., and / or Escherichia spp.
[0049] In particular, bovine mastitis can be caused by Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus lactis, Streptococcus brasiliensis, Streptococcus agalactiae, and / or Escherichia coli.
[0050] In addition, bovine mastitis can be caused by Cryptococcus pyogenes and / or Escherichia coli.
[0051] The present invention also relates to a method for treating mastitis, the method comprising the step of administering a therapeutically effective amount of lysozyme and at least one aminoglycoside antibiotic to a female non-human animal having and requiring mammary glands. Preferably, the female non-human animal having mammary glands is a dairy cow.
[0052] Finally, although the main aspects of this invention relate to the treatment of mastitis (particularly bovine mastitis) for commercial applications, the synergistic effects unexpectedly discovered herein are not limited to specific treatments of the udder (particularly bovine udder). Experimental data provided herein demonstrate that the aforementioned synergistic effects are applicable to the treatment of any non-human animal suffering from any disease caused by Gram-negative and Gram-positive bacteria.
[0053] Therefore, general embodiments of the present invention typically involve a combination of lysozyme and at least one aminoglycoside antibiotic for the treatment of non-human mammals against diseases caused by Gram-negative and Gram-positive bacteria. Attached Figure Description
[0054] The invention will be further illustrated with reference to the following embodiments and accompanying drawings, but is not limited thereto.
[0055] Figure 1 The killing kinetics of lysozyme against Staphylococcus aureus and Streptococcus lactis were demonstrated (Example 2).
[0056] Figure 2 The changes in the MIC of lysozyme against Staphylococcus aureus and Streptococcus lactis during continuous passage are shown (Example 4).
[0057] Figure 3 This demonstrates the efficacy of lysozyme in a Staphylococcus aureus acute mouse mastitis model (Example 5).
[0058] Figure 4 This demonstrates the efficacy of lysozyme in a mouse model of mastitis caused by Streptococcus mammatidis (Example 6).
[0059] Figure 5 The concentration-time curve of lysozyme in milk after intramammary ampoule (IMAM) administration to lactating Holstein cows is shown (Example 7).
[0060] Figure 6 The killing kinetics of lysozyme and neomycin against Staphylococcus aureus and Streptococcus lactis in milk, alone or in combination at 1:1 and 2:1 dose ratios, were demonstrated (Example 10).
[0061] Figure 7 The killing kinetics of lysozyme and neomycin against Staphylococcus aureus and Streptococcus lactis in milk, alone or in combination at dose ratios of 1:5 and 1:10, were demonstrated (Example 10).
[0062] Figure 8 The killing kinetics of lysozyme and neomycin alone or in combination against Escherichia coli in milk were demonstrated (Example 10).
[0063] Figure 9The killing kinetics of lysozyme conjugates with neomycin or kanamycin against Staphylococcus aureus were demonstrated (Example 11).
[0064] Figure 10 The killing kinetics of the lysin-florfenicol conjugate against Staphylococcus aureus and Streptococcus lactis were demonstrated (Example 12).
[0065] Figure 11 The combined or individual efficacy of lysozyme and neomycin in a Staphylococcus aureus acute mouse mastitis model was demonstrated (Example 13).
[0066] Figure 12 The combined or individual efficacy of lysozyme and neomycin in an acute mouse model of mastitis caused by Streptococcus mammatidis was demonstrated (Example 14).
[0067] Example:
[0068] Example 1: In vitro antibacterial activity of lysozyme alone against mastitis pathogens
[0069] The in vitro antimicrobial activity of lysozyme against common mastitis pathogens such as Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus lactis, Streptococcus brasiliensis, Streptococcus agalactiae, Cryptococcus pyogenes, Escherichia coli, or Klebsiella pneumoniae is assessed using the microbroth dilution MIC method as described by the Clinical and Laboratory Standards Institute (CLSI) to obtain the minimum inhibitory concentration (MIC), defined as the lowest concentration of the substance that prevents visible bacterial growth. MIC is expressed as... 90 The results are summarized in the table below, where MIC 90 Defined as the concentration that inhibits the growth of at least 90% of strains of a given species.
[0070]
[0071] Example 2: In vitro killing kinetics of lysozyme alone against mastitis pathogens
[0072] To evaluate the ability of lysozyme to kill bacteria in milk, flasks containing different concentrations of lysozyme from commercially available whole milk were inoculated with 1-2 × 10⁻⁶ flasks. 6 Representative strains of Staphylococcus aureus or Streptococcus lactis per colony-forming unit / ml. Incubate the flasks in a shaking water bath at 35 ± 2 °C for 24–48 hours, and determine the viable bacterial count in each flask at several time points by diluting and inoculating the samples on agar plates. Bactericidal activity is defined as a reduction of at least 99.9% in the number of viable bacteria in the initial inoculum.
[0073] The kinetics of lysozyme against Staphylococcus aureus ATCC 29740 and Streptococcus lactis ATCC 27958 in milk were determined at concentrations of 4, 8, 16, 32, and 64 μg / mL. The results are as follows: Figure 1 As shown (CFU: colony-forming unit). For Staphylococcus aureus and Streptococcus lactis, the kill rate (cidality) at 24 hours and 48 hours can be assumed, respectively.
[0074] Example 3: In vitro assessment of spontaneous resistance development to lysin alone:
[0075] Inoculate at least 1 x 10⁻⁶ cells onto agar plates containing 4x or 8x MIC lysozyme. 9 Individual bacterial strains from colony-forming units were incubated on plates at 35 ± 2 °C to assess the frequency of spontaneous resistance development. After 48 h, the number of colonies grown on the plates at lysozyme concentrations above the MIC was divided by the initial number of bacteria inoculated onto the plates. The resulting number was defined as the spontaneous resistance frequency and represents the likelihood of resistant isolates emerging during infection.
[0076] In summary, lysozyme at 4 and 8 times the MIC showed a very good resistance spectrum: no resistant isolates were detected. The results are summarized in the table below:
[0077] Staphylococcus aureus ATCC 29740:
[0078]
[0079] Streptococcus mammati ATCC 27958:
[0080]
[0081] Example 4: During continuous passaging For lysozyme alone In vitro assessment of drug resistance development
[0082] MIC changes during continuous bacterial exposure to subMIC concentrations of lysozyme were assessed using sequential passage experiments. On day 1, the MICs of Staphylococcus aureus and Streptococcus lactis were assessed using the microbroth dilution MIC method, as described by the Clinical and Laboratory Standards Institute (CLSI). Over the next 33 days, bacteria were collected daily from wells containing the highest concentration allowed for complete growth and used to inoculate new 96-well plates, and the MICs during continuous exposure to lysozyme were assessed. The daily MICs were plotted over time. Results are as follows: Figure 2 As shown. Rifampin, known to cause rapid changes in MIC, was used as a positive control.
[0083] The results showed that lysozyme was very effective in characterizing the development of resistance during sustained exposure, as the MICs of Staphylococcus aureus and Streptococcus lactis remained constant over 33 days.
[0084] Example 5: Efficacy of lysozyme alone in an acute mouse model of mastitis caused by Staphylococcus aureus
[0085] The efficacy of lysozyme (prepared in a hydrogel at pH 4.7) was tested in an acute mouse model of Staphylococcus aureus mastitis established at the University of Sherbrooke, Canada (Brouillette et al., Vet. Microbiol. (2004) 4:253-262), and is incorporated herein by reference. The abdominal mammary glands (L4 and R4) of lactating CD-1 mice were intramammarily infected with 100 CFU (colony-forming units) of Staphylococcus aureus. Four hours post-infection, mice were intramammarily treated with lysozyme. Each treatment group contained at least three mice (six regions). Mice were sacrificed 14 hours later (18 hours post-inoculation), and mammary glands were collected. CFU content was assessed by agarizing with serially diluted mammary gland homogenates (10-fold). CFU content is expressed as log... 10 Counting. The detection limit is 200 CFU / g glands. Glands below 200 CFU / g are considered cleared. Results are as follows: Figure 3 As shown.
[0086] Intramammary infusion of 50 μg lysozyme reduced the median CFU level by approximately 4 log. 10 400 μg of lysozyme eliminated infection in all infected glands.
[0087] Example 6: Efficacy of lysozyme alone in an acute mouse model of mastitis caused by Streptococcus mammatidis.
[0088] The efficacy of lysozyme (prepared in a hydrogel at pH 4.7) was tested in a mouse model of mastitis challenged by *Streptococcus mammologica*. Results are as follows: Figure 4 As shown.
[0089] Twenty lactating mice were experimentally infected with *Streptococcus mammaria* on the fourth pair of mammary glands approximately 12–15 days after birth. Four hours after inoculation, four mice were treated with lysozyme formulated as a hydrogel at doses of 100, 200, 400, or 800 μg / glandule on the same glands. A fifth group was treated with only the hydrogel carrier as a negative control. Eighteen hours post-infection, the animals were euthanized, the glands were removed, homogenized, and bacterial colony-forming units (CFU) were determined using established microbiological methods. CFU / mL homogenate and CFU / g glandule were then calculated. The limit of detection was approximately 100 CFU / g glandule. The antimicrobial activity of lysozyme against *Streptococcus mammaria* was determined by comparing the mean CFU / glandule ratio of different dose groups and the negative control group.
[0090] In the control group, the glands of all animals showed the best infection rate (≥10%) 18 hours after infection. 7 CFU / g gland). There was one exception in the highest dose group; all glands in the lysin-treated group had levels below the limit of detection (10 CFU / g gland). 2 Bacterial counts (CFU / g) were performed. It can be concluded that lysozyme formulated as a hydrogel exhibits outstanding antibacterial efficacy against Streptococcus mammologica at intramammary doses ranging from 100 to 800 μg / gland.
[0091] Example 7: In vivo bovine data for lysozyme alone - a pharmacokinetic study of milk in lactating Holstein cows.
[0092] This study was designed as a non-critical study applicable to investigating the pharmacokinetics of the active substance lysozyme after a single intracerebral administration to lactating dairy cows.
[0093] The active substance is provided in a paraffin-based service formulation suitable for intracerebrospinal administration, containing 150 mg of lysozyme in a 10 g oil suspension.
[0094] The test substance was administered to a single posterior region of each of the four lactating cows as a single intracranial treatment at a dose rate of 150 mg lysozyme.
[0095] The Holstein cows in the study represented a target population based on age, number of lactations, lactation period, milk yield, and breed. These animals were kept in tethered barns and fed a standard dairy cow diet consisting of corn and hay silage, along with milk performance feed. They were milked twice daily at 12-hour intervals using bucket milking equipment.
[0096] Milk samples were frequently taken from the treated area and its respective control area by manual dissection of individual mammary gland regions before (0 h) and during the 168 h period following treatment (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, and 168 h). Milk samples were collected at the regular milking time prior to milking.
[0097] The concentration of the active substance lysozyme in milk was analyzed by HPLC and detected by tandem mass spectrometry. The limit of quantitation was 0.05 mg / L.
[0098] The pharmacokinetic assessment of milk concentration data is based on a non-compartmental approach and includes PK parameters to fully characterize the absorption, distribution, and elimination of active substances in milk.
[0099] Summary results from treated breast regions are shown in the table below. Lysozyme was not detected in the control samples (untreated breast regions).
[0100]
[0101] The concentration-time curve of lysozyme is shown in Figure 5 middle.
[0102] Example 8: In vivo bovine data from lysin alone - a bovine mammary gland infection model of Staphylococcus aureus.
[0103] Fifteen healthy lactating cows were experimentally infected with Staphylococcus aureus, the mastitis pathogen, in all four udder regions. Once clinical signs of mastitis appeared in the udder region, such as swelling, pain, and abnormal milk consistency, treatment was administered as a negative control with two different concentrations of lysozyme paraffin-based ointment or Ubrolexin® (cephalosporin + kanamycin, Boehringer Ingelheim) or saline solution. Treatment was randomly assigned to a total of 42 udder regions, with either 50 mg of lysozyme per region (in 11 regions), or 150 mg of lysozyme per region (in 11 regions), or Ubrolexin per region. ® (In 9 areas), or saline solution (in 11 areas). Before treatment (n=42), only breast areas immediately bacteriologically positive for the attacking organism were suitable for evaluation of microbiological and clinical cure. The affected areas were treated twice with these intramammary preparations at 24-hour intervals. The breast was clinically examined and milk samples were collected before treatment, and several times thereafter until three weeks after the second administration. The consistency of the milk was visually examined to assess the presence of the attacking organism in the samples, and somatic cell counts were assessed to confirm the diagnosis of mastitis. The affected breast area was considered microbially cured when Staphylococcus aureus found in the milk sample shortly before treatment could not be isolated from any milk sample collected between day 3 and day 21 after the second treatment. Clinical cure was achieved when the local symptoms of mastitis completely disappeared, and when all counts remained below 500,000 cells / mL milk during the above-mentioned period, somatic cell counts (SCC), a parameter of breast inflammation, were restored.
[0104] The microbial cure rates on days 3 and 21 after the second treatment were 73% and 27% for lysozyme 50 mg and 73% and 45% for lysozyme 150 mg, respectively, and for ubroxin. ® The local clinical cure rates were 78% and 44% for lysine and 0% for saline solution, respectively. On day 3 and day 21 after the second treatment, the local clinical cure rates were 45% and 73% for lysine 50 mg, 37% and 82% for lysine 150 mg, and for ubroxin... ® The rates were 33% and 67% for lysine and 55% and 73% for saline solution. The SCC recovery rates on days 3 and 21 after the second treatment were 36% and 45% for lysine 50 mg, 36% and 91% for lysine 150 mg, and for ubroxin...® The concentrations were 56% and 67% for the first two solutions and 36% and 27% for the second two solutions, respectively.
[0105] It can be concluded that, compared with the positive control product Ubrolexin... ® In comparison, lysozyme 150 mg showed similar or even better efficacy and was superior to lysozyme 50 mg and saline solution in parametric microbiology and clinical cure as well as SCC recovery.
[0106] Example 9: In vivo bovine data from lysin alone - a bovine mammary gland infection model of Streptococcus mammarius.
[0107] Seventy-two healthy lactating dairy cows were experimentally infected with the mastitis pathogen Streptococcus mammologicus in two udder areas of each cow. Once clinical signs of mastitis appeared in the udder area (such as heat, swelling, redness, pain, and abnormal milk consistency), the cows were treated with two different concentrations of lysin paraffin-based ointment or Ubrolexin® (cephalosporin + kanamycin, Boehringer Ingelheim).
[0108] Treatment was randomized to a total of 41 (clinical) or 37 (microbial) breast regions, with 50 mg of lysozyme per region (in 15 / 13 regions), or 150 mg of lysozyme per region (in 15 / 14 regions), or Ubrolexin. ® (In 11 / 10 areas) served as a positive control. The affected area was treated twice with these intramammary preparations at 24-hour intervals. The breast was clinically examined, and milk samples were collected before treatment and several times thereafter, up to three weeks after the second application. The consistency of the milk was visually examined to assess the presence of attacking organisms in the samples to confirm the diagnosis of mastitis. The affected breast area was considered microbially cured when *Streptococcus lactis* found in the milk sample shortly before treatment could not be isolated from any milk samples collected between day 7 and day 21 after the second treatment. Clinical cure was achieved when the local symptoms of mastitis completely disappeared or were of a very mild nature.
[0109] The microbial cure rates on days 7 and 21 after the second treatment were 84.6% and 92.31% for lysozyme 50 mg and 71.4% and 85.71% for lysozyme 150 mg, respectively, and for umbellatus... ® The rates were 30% and 30%. The local clinical cure rate on day 7 after the second treatment was 86.7% for both lysozyme 50 mg and lysozyme 150 mg, and for Ubrolexin... ® It is 36.4%.
[0110] It can be concluded that Ubrolexin is a positive control product in key parameters of microbiology and clinical cure.® In comparison, lysozyme 50 and 150 mg are significantly more effective.
[0111] Example 10: In vitro killing kinetics of mastitis pathogens by the conjugate of lysin and neomycin
[0112] To evaluate the in vitro synergistic activity of lysozyme and neomycin in commercially available whole milk, flasks containing different concentrations of lysozyme and neomycin (alone or in combination) were inoculated with 1–2 × 10⁻⁶ mol / L flasks. 6 Representative strains of Staphylococcus aureus, Streptococcus lactis, or Escherichia coli per colony-forming units ( / ml).
[0113] The flasks were incubated in a shaking water bath at 35 ± 2 °C for 24–48 hours, and the viable bacterial count in each flask was determined at several time points by diluting and inoculating the samples on agar plates.
[0114] After 24 h, a reduction of at least 99% in the number of viable bacteria achieved by combination compared to the most active single compound was defined as synergistic activity (NCCLS / CLSI M26-A Vol.19, No.18).
[0115] Determination of the killing kinetics of lysozyme and neomycin (alone or in combination) against Staphylococcus aureus ATCC 29740 in milk at concentration ratios of 1:1 (2 μg / ml each) and 2:1 (2 μg / ml lysozyme and 1 μg / ml neomycin).
[0116] The results are as follows Figure 6 As shown.
[0117] Synergistic activity of the lysozyme:neomycin conjugate was observed after 24 hours. The synergistic effect was most pronounced at a ratio of at least 2:1, particularly at a ratio of 1:1.
[0118] Determination of the killing kinetics of lysozyme and neomycin (alone or in combination) against Streptococcus lactis ATCC 27958 in milk at concentration ratios of 1:1 (16 μg / ml each) and 2:1 (16 μg / ml lysozyme and 8 μg / ml neomycin).
[0119] The result was as expected. Figure 6 As shown.
[0120] After 24 hours, synergistic activity of the lysozyme:neomycin conjugate could be observed at both ratios.
[0121] Determination of the killing kinetics of lysozyme and neomycin (alone or in combination) against Staphylococcus aureus ATCC 29740 in milk at a concentration ratio of 1:5 (1 μg / ml lysozyme plus 5 μg / ml neomycin and 1.5 μg / ml lysozyme plus 7.5 μg / ml neomycin, respectively).
[0122] The results are as follows Figure 7 As shown.
[0123] Synergistic activity was observed after 24 hours. The synergistic effect was already very significant when the lysozyme:neomycin ratio was at least 1:5 (i.e., 0.2). This synergistic effect was independent of the absolute amounts of lysozyme and neomycin used. Figure 7 As proven.
[0124] Determination of the killing kinetics of lysozyme and neomycin (alone or in combination) against Streptococcus lactis ATCC 27958 in milk at a concentration ratio of 1:10 (1 μg / ml lysozyme plus 10 μg / ml neomycin and 2 μg / ml lysozyme plus 20 μg / ml neomycin, respectively).
[0125] The result was as expected. Figure 7 As shown.
[0126] Synergistic activity was observed after 24 hours. At a lysozyme:neomycin ratio of 1:10 (0.1), the synergistic effect was very significant regardless of the absolute amounts of lysozyme and neomycin.
[0127] In summary, synergistic activity of the lysozyme:neomycin conjugate can be demonstrated. This synergistic activity was particularly evident for Staphylococcus aureus ATCC29740 and Streptococcus lactis ATCC 27958 at ratios of 2:1 to 1:5 (0.2) and 2:1 to 1:10 (0.1), respectively.
[0128] The killing kinetics of lysozyme and neomycin (alone or in combination) against Escherichia coli P4:O32 in milk were determined at a concentration ratio of 4:1 (256 μg / ml lysozyme and 32 μg / ml neomycin).
[0129] The results are as follows Figure 8 As shown.
[0130] Although neomycin and lysozyme:neomycin conjugate can reduce bacterial cell counts below the detection limit after 8 hours, the conjugate shows a faster killing effect.
[0131] Furthermore, the complex effectively prevents bacterial regrowth after 24 hours, which is something that the individual active ingredients cannot achieve.
[0132] Therefore, synergistic activity was also observed here for Gram-negative Escherichia coli.
[0133] Example 11: The effect of a conjugate of lysozyme with neomycin or kanamycin on Staphylococcus aureus ATCC 29740 In vitro killing kinetics
[0134] To investigate whether the aforementioned synergistic effect is indeed applicable to more aminoglycoside antibiotics besides neomycin in combination with lysozyme, the killing kinetics of kanamycin as a combination partner were also tested.
[0135] Kill dynamics are performed as described in Example 10.
[0136] The kinetics of lysozyme:neomycin or lysozyme:kanamycin concentration ratio of 1:4 (0.5 μg / ml lysozyme plus 2 μg / ml neomycin or kanamycin; 1 μg / ml lysozyme plus 4 μg / ml neomycin or kanamycin; and 2 μg / ml lysozyme plus 8 μg / ml neomycin or kanamycin, respectively) against Staphylococcus aureus ATCC 29740 in milk were determined.
[0137] The results are as follows Figure 9 As shown.
[0138] For all concentrations evaluated, the lysozyme:kanamycin conjugate showed similar activity compared to the lysozyme:neomycin conjugate.
[0139] Therefore, it can be concluded that the combination of lysozyme and aminoglycoside antibiotics exhibits an unexpected synergistic effect.
[0140] Comparative Example 12: The effect of the conjugate of lysozyme and florfenicol on Staphylococcus aureus ATCC 29740 and lactobacillus In vitro killing kinetics of Streptococcus aureus ATCC 27958
[0141] The synergistic activity of two different antibiotics is not reliably predictable, as shown below.
[0142] For example, the conjugate of lysozyme and florfenicol in Figure 10 No synergistic activity was observed against Staphylococcus aureus ATCC 29740 and Streptococcus lactis ATCC 27958 in milk under the test conditions shown.
[0143] Example 13: The conjugate of lysin and neomycin trisulfate in acute mouse milk effusion of Staphylococcus aureus Efficacy in adenoitis model
[0144] The efficacy of lysozyme and neomycin trisulfate (alone or in combination) was tested in a mouse model of acute Staphylococcus aureus mastitis established at the University of Sherbrooke, Canada (Brouillette et al., Vet. Microbiol. (2004) 4:253-262), as described in Example 5. Samples were prepared in paraffin.
[0145] The results are as follows Figure 11 As shown.
[0146] Intramammary infusion of 50 μg lysin, 1600 μg neomycin trisulfate, and a combination of 50 μg lysin and 1600 μg neomycin trisulfate reduced the median CFU level by approximately 2.7, 2.5, and 5.9 log, respectively. 10 .
[0147] Example 14: The conjugate of lysin and neomycin trisulfate in acute mouse mastitis caused by Streptococcus mammatidis. Power in the model
[0148] Ten to fifteen days after the offspring were born, the left and right fourth mammary glands of 23 lactating CD-1 mice were experimentally infected with the mastitis pathogen Streptococcus mammologicus (ATCC 27958).
[0149] Four hours after infection, the animals were treated intramammarily with the test substance. The study included four treatment groups, with four mice in each group, and a control group of seven mice.
[0150] Mice in the treatment group received a paraffin-embedded formulation of lysozyme at 15 μg / gland or neomycin trisulfate at 1600 μg / gland, or a combination of lysozyme at 15 μg and neomycin trisulfate at 800 μg or 1600 μg / gland.
[0151] Eighteen hours after infection, mice were killed and mammary glands were removed, and bacterial CFU was evaluated microbiologically.
[0152] The results are as follows Figure 12 As shown.
[0153] The control group receiving paraffin as a placebo performed as expected, with a CFU of approximately 7 log. 10 / g tissue. Intramammary infusion of 15 μg lysin, 1600 μg neomycin trisulfate, and a conjugate of 15 μg lysin and 1600 μg neomycin trisulfate reduced the average CFU content by approximately 2.6, 1.5, and 3.8 log, respectively. 10 .
[0154] It can be concluded that the lysozyme / neomycin trisulfate conjugate administered at 15 / 1600 μg / glandular dose is superior in efficacy against Streptococcus lactis ATCC27958 compared to their single components at the same dose.
[0155] Example 15: In vivo bovine data from lysozyme and neomycin trisulfate - Staphylococcus aureus in the udder of dairy cows Infection model
[0156] Fifteen healthy lactating cows were experimentally infected with Staphylococcus aureus, the mastitis pathogen, in all four udder areas. Once clinical signs of mastitis appeared in the udder area, such as swelling, pain, and abnormal milk consistency, the cows were treated with a 50 mg miglyol-based suspension of lysin, or a 400 mg miglyol-based neomycin trisulfate, or a combination of both, i.e., 50 mg lysin and 400 mg neomycin trisulfate.
[0157] In addition, a fourth group of breast areas received miglyol as a negative control. Treatment was randomly assigned to a total of 60 breast areas. Before treatment (n=49), only breast areas that were immediately bacteriologically positive for the attacking organism were suitable for evaluation of microbiology and clinical cure. The affected areas were treated twice with these intramammary preparations at 24-hour intervals. The breasts were clinically examined and milk samples were collected before treatment, and several times thereafter until three weeks after the second administration, during which time the researchers were unaware of the treatment.
[0158] Visually inspect the milk for consistency deviations, assess the presence of aggressive organisms in the samples, and evaluate somatic cell counts to confirm the diagnosis of mastitis. The affected breast area is considered microbially cured when Staphylococcus aureus found in milk samples shortly before treatment cannot be isolated from any milk samples collected between day 3 and day 21 after the second treatment. Clinical cure is achieved when local symptoms of mastitis completely disappear, and the somatic cell count (SCC), a parameter of breast inflammation, is restored when all counts remain below 200,000 cells / mL milk during the aforementioned period.
[0159] The microbial cure rates on days 3 and 21 after the second treatment were 71% and 14% for lysozyme 50 mg, 100% and 42% for neomycin trisulfate 400 mg, 69% and 54% for the combination of lysozyme 50 mg and neomycin trisulfate 400 mg, and 10% and 30% for the negative control miglyol.
[0160] The local clinical cure rates on days 3 and 21 after the second treatment were 71% and 71% for lysozyme 50 mg, 67% and 100% for neomycin trisulfate 400 mg, 77% and 85% for the conjugate of lysozyme 50 mg and neomycin trisulfate 400 mg, and 80% and 70% for the negative control miglyol.
[0161] The recovery rates of SCC on days 3 and 21 after the second treatment were 35% and 36% for lysozyme 50 mg, 17% and 50% for neomycin trisulfate 400 mg, 46% and 69% for the conjugate of lysozyme 50 mg and neomycin trisulfate 400 mg, and 30% and 30% for the negative control miglyol.
Claims
1. A combination of lysozyme and neomycin used to treat bovine mastitis caused by Staphylococcus and / or Streptococcus bacteria. The ratio of lysozyme to neomycin is 8:1, 2:1, 1:1, 1:4, 1:5, or 1:
10.
2. A combination of lysozyme and kanamycin used to treat bovine mastitis caused by Staphylococcus and / or Streptococcus bacteria. The ratio of lysozyme to kanamycin is 1:
4.
3. The therapeutic conjugate according to claim 1 or 2, wherein the conjugate is administered intramammarily.
4. The combination for treatment according to any one of claims 1 to 3, wherein the bovine mastitis is clinically evident bovine mastitis.
5. The combination for treatment according to any one of claims 1 to 4, wherein the bovine mastitis is subclinical bovine mastitis.
6. The therapeutic conjugate according to any one of claims 1 to 5, wherein lysozyme is provided at a dose of 25 to 1000 mg per breast area.
7. The therapeutic conjugate of claim 6, wherein lysozyme is provided at a dose of 50 to 500 mg per breast area.
8. The therapeutic conjugate of claim 6, wherein lysozyme is provided at a dose of 100 to 300 mg per breast area.
9. The therapeutic conjugate of claim 6, wherein lysozyme is provided at a dose of 50 mg per breast area.
10. The therapeutic conjugate of claim 6, wherein lysozyme is provided at a dose of 150 mg per breast region.
11. The combination for treatment according to any one of claims 1 to 10, wherein bovine mastitis is caused by Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus lactis, Streptococcus brasiliensis, Streptococcus agalactiae, and / or Escherichia coli.
12. A pharmaceutical composition for intramammary administration into the udder of a cow, characterized in that... The composition comprises lysozyme and neomycin, wherein the ratio of lysozyme to neomycin is 8:1, 2:1, 1:1, 1:4, 1:5, or 1:
10.
13. A pharmaceutical composition for intramammary administration into the udder of a cow, characterized in that... The composition comprises lysozyme and kanamycin, wherein the ratio of lysozyme to kanamycin is 1:
4.
14. A method for treating mastitis, the method comprising the step of administering a therapeutically effective amount of lysozyme and neomycin to a female nonhuman animal in need of treatment. The ratio of lysozyme to neomycin is 8:1, 2:1, 1:1, 1:4, 1:5, or 1:
10.
15. A method for treating mastitis, the method comprising the step of administering therapeutically effective amounts of lysin and kanamycin to a female nonhuman animal in need of treatment. The ratio of lysozyme to kanamycin is 1:4.
Citation Information
Patent Citations
Antibiotic prepared from lysobacter sp. SC 14,067
EP0196042A2
Katanosin a and b and their production
JP1989132600A
Antibiotic prepared from lysobacter sp. SC 14,067 and analogs thereof
US4754018A
Acylated lysobactin-type nonadepsipeptides
WO2004099239A1
Heterocyclyl-substituted nonadepsipeptides
WO2006042653A1
